Block TNF to boost immune response in melanoma
Part of Cancer, Skin clinical trials.
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently enrolled in the TICIMEL trial (NCT03293784).
- You are currently enrolled in the MELANFα trial (NCT03348891).
- You meet the study’s setup/eligibility rules to join this add-on treatment while in those trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This early study tests whether “immune recall” (training the immune system using specific vaccine-like steps) can improve how well checkpoint drugs work for advanced melanoma. It is designed mainly to see if the approach is feasible and safe, and it may help some people respond better to PD-1 (with or without CTLA-4) treatment.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.